July 2021 Alzheimer’s News

July 2021 Alzheimer’s News
The Food and Drug Administration (FDA) approval of aducanumab (AduhelmTM) from Biogen — the first drug to slow the progression of Alzheimer’s disease — is a milestone in the treatment of the disease and a beginning of a completely new future for Alzheimer’s treatments. This treatment, while not a cure, is pivotal and current progress in science is significant. We expect this will be the first of a number of treatments to come.

As a new type of Alzheimer’s treatment, aducanumab addresses the disease in a way that has never been done before. This therapy slows progression of the disease, rather than only addressing symptoms.
This infusion treatment will reduce the buildup of amyloid plaques, one of the hallmarks of Alzheimer’s in the brain. Thus, giving the patient more time to enjoy family and doing things they like in the early stages of the disease. It does require early diagnosis from a qualified doctor or neurologist. And the diagnosis must be Alzheimer’s, not dementia.
Early detection in Alzheimer’s disease is more important now than ever with a treatment available. Early diagnosis has long demonstrated better health outcomes for individuals and their caregivers. If you or a loved one is experiencing memory changes, the Alzheimer’s Association strongly encourages speaking with a health care provider for a thorough evaluation, diagnosis and to discuss treatment options.
You can learn more by going to www.alz.org/help-support/resources or the Alzheimer’s Helpline which is accessible 24/7 via 800-272-3900 and staffed by master’s level clinicians to assist with crisis situations, decision making, and disease information. You can find virtual dementia caregiver resources online at alz.org/covid19help. Tools and support are also available in Spanish.
Want to learn more about the Alzheimer’s Association and what they do here in St. Louis? Visit alz.org and/or contact PUCC’s Faith Outreach Ambassador with the Alzheimer’s Association, Joyce Ruiz at joyceruiz7@gmail.com.